Brief: Immunovant Provides Development Updates And Reports Financial Results For The Quarter Ended September 30, 2024
07/11/2024 13:13
Nov 7 (Reuters) - Immunovant Inc IMVT.O :
* IMMUNOVANT PROVIDES DEVELOPMENT UPDATES AND REPORTS
FINANCIAL
RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2024
* IMMUNOVANT: AS OF SEPT 30, 2024, IMMUNOVANT'S CASH AND
CASH
EQUIVALENTS TOTALED ABOUT $472.9 MILLION
Source text: ID:nGNX18cvwF
Further company coverage: IMVT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million